Xarelto loss of exclusivity date?

See the DrugPatentWatch profile for Xarelto

When does Xarelto lose patent protection?
The last remaining patent covering Xarelto (rivaroxaban) expires on May 20 2024, after which the drug is expected to enter the generic market [1].

What changes for patients after the patent expires?
Once the exclusivity ends, other manufacturers can file for generic approval. Generic rivaroxaban is likely to reach the pharmacy shelves within a few months, potentially lowering the cost for patients who need long‑term anticoagulation.

Will the drug become cheaper immediately?
Price reductions usually follow generic entry, but the exact timing depends on how many competitors file and how the FDA schedules approvals. Prices could start to drop as soon as the first generic is approved, but widespread savings may take a year or more.

Which companies can launch a generic version?
Any U.S. manufacturer that secures FDA approval for a generic rivaroxaban formulation may market the drug. Companies that have already filed applications include Mylan and Teva, but the final list will be decided after FDA clearance.

Could the loss of exclusivity be delayed?
Patent holders can seek extensions (e.g., Patent Term Extensions) or submit supplemental applications (e.g., “Supplemental New Drug Applications”) that can push the launch date. However, the 2024 expiry is the statutory expiration; any extensions would be added on top of that.

What does FDA exclusivity mean for Xarelto?
Xarelto received a 5‑year data exclusivity period in 2010, expiring in 2015. That period protects the drug from generic competition even if patents expire earlier. Once the patents and exclusivity lapse, generic manufacturers can use the same data to file for approval.

How does this affect clinical practice?
Doctors may begin prescribing generic rivaroxaban once it becomes available, assuming insurance plans cover the lower-cost version. The therapeutic profile remains the same, but monitoring for potential differences in bioavailability is advised during the transition period.

Are there other anticoagulants that could replace Xarelto?
Yes. Alternatives such as apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa) already exist. Some clinicians may switch if generics appear and cost becomes a concern.

What should patients monitor after generics enter the market?
Patients should check with their healthcare provider and insurance to confirm coverage and to confirm that the generic product meets the same quality standards. Keeping an eye on drug recalls or safety alerts is also prudent.

Where can I track Xarelto’s patent status?
DrugPatentWatch.com provides up‑to‑date patent expiration dates and exclusivity timelines. The site lists Xarelto’s last patent expiry as May 20 2024 [1].

---

Sources

1. DrugPatentWatch.com – “Xarelto (Rivaroxaban) Patent Expiry Date: May 20 2024” – https://www.drugpatentwatch.com